Free Trial
→ My feud with Zohran Mamdani (From Stansberry Research) (Ad)tc pixel
NASDAQ:ICCM

IceCure Medical Q3 2026 Earnings Date & Estimates

IceCure Medical logo
$0.87 -0.09 (-9.05%)
Closing price 10/30/2026 03:59 PM Eastern
Extended Trading
$0.92 +0.05 (+5.62%)
As of 10/30/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IceCure Medical is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. The conference call is scheduled for 10:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
10:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from IceCure Medical in Q3 2026

IceCure Medical is expected to post earnings of -$0.83 per share on revenue of $876 thousand. In the same quarter a year earlier IceCure Medical reported -$1.80 per share on revenue of $850 thousand. IceCure Medical has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.83
Expected Revenue
$876 thousand
Prior-Year EPS
-$1.80
Prior-Year Revenue
$850 thousand
Expected Revenue Growth
+3.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.60
Last Quarter Revenue
$907 thousand
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

IceCure Medical Q3 2026 Earnings FAQ

IceCure Medical (NASDAQ:ICCM) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

IceCure Medical's Q3 2026 earnings conference call is scheduled for Wednesday, November 18, 2026 at 10:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect IceCure Medical to post earnings of -$0.83 per share for Q3 2026.

The consensus revenue estimate for IceCure Medical is $876 thousand for Q3 2026.

IceCure Medical Earnings Headlines

IceCure Medical: IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
October 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69948234-icecure-medical-icecure-successfully-completes-first-cryoablation-treatment-in-its-choice-post-marketing-study-for-breast-cancer-cryoablation-008.htm
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
October 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/icecure-successfully-completes-first-cryoablation-treatment-in-its-choice-post-marketing-study-for-breast-cancer-cryoablation-302920719.html
Why Gerardo Del Real says wait before buying uranium stocks
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
 |  Digest Publishing (Ad)
IceCure Medical: IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites
October 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69884100-icecure-medical-icecure-enrolls-first-patients-in-its-fda-approved-study-for-prosense-breast-cancer-cryoablation-at-two-u-s-sites-008.htm
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
October 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/icecure-enrolls-first-patients-in-its-fda-approved-study-for-prosense-breast-cancer-cryoablation-at-two-us-sites-302913757.html
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
October 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html
See More IceCure Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email.

About IceCure Medical

IceCure Medical (NASDAQ:ICCM) is an Israel-based medical technology company focused on minimally invasive cryoablation treatments for cancerous and benign tumors. Its technology uses extremely cold temperatures, generated by liquid nitrogen, to destroy targeted tissue while limiting damage to surrounding areas.

The company’s primary product is the ProSense Cryoablation System, which consists of a console, cryoprobes and related components. The system is designed to freeze and ablate tumors through a percutaneous procedure, generally under image guidance. IceCure has developed applications for tumors in areas including the breast, kidney, liver and bone.

IceCure markets its technology internationally and has pursued regulatory clearances and clinical development in the United States, Europe and other global markets. The company’s products are intended to support less invasive treatment options and, in certain cases, may be used as an alternative or complement to surgery and other cancer therapies.

View IceCure Medical Profile
Earnings Tools